Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.

Hypertension (Dallas, Tex. : 1979) - 1 Oct 2012

Vandell Alexander G, Lobmeyer Maximilian T, Gawronski Brian E, Langaee Taimour Y, Gong Yan, Gums John G, Beitelshees Amber L, Turner Stephen T, Chapman Arlene B, Cooper-DeHoff Rhonda M, Bailey Kent R, Boerwinkle Eric, Pepine Carl J, Liggett Stephen B, Johnson Julie A

Abstract excerpt

G protein-coupled receptor kinases (GRKs) are important regulatory proteins for many G protein-coupled receptors, but little is known about GRK4 pharmacogenetics. We hypothesized that 3 nonsynonymous GRK4 single-nucleotide polymorphisms, R65L (rs2960306), A142V (rs1024323), and A486V (rs1801058), would be associated with blood pressure response to atenolol, but not hydrochlorothiazide, and would be associated...

Read the complete abstract on PubMed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Adrenergic beta-Antagonists
Share to Blood Pressure
Share to Calcium Channel Blockers
Share to Coronary Artery Disease
Share to Hydrochlorothiazide
Share to Pharmacogenetics
Share to Verapamil

Source

Open in PubMed Open full text

Identifiers

PMID: 22949529
DOI: 10.1161/HYPERTENSIONAHA.112.198721
PMCID: PMC3462355

Genes

GRK4
ADRB1

Variants

rs2960306
rs2960306
rs2960306

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.PMID 22949529Read ↗

Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.Semantic proximity Read ↗

Common variants of the G protein-coupled receptor type 4 are associated with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade.Semantic proximity Read ↗

KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).Semantic proximity Read ↗

Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).Semantic proximity Read ↗

β-Adrenergic Receptor Gene Polymorphisms and β-Blocker Treatment Outcomes in HypertensionSemantic proximity Read ↗

Pharmacogenetics of antihypertensive treatment.Semantic proximity Read ↗

G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions.Semantic proximity Read ↗

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.Semantic proximity Read ↗

Pharmacogenetic factors affecting β-blocker metabolism and response.Semantic proximity Read ↗

CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.Semantic proximity Read ↗

Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patientsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.